GFAP and Alzheimer disease: Specifically, we found that the upregulation of astroglial markers GFAP and AQP4 following treatment with ZLE or tricin may help mitigate deficits in the Aβ clearance pathway, as evidenced by the enhanced expression of LRP1 and MMPs, which are critical in the pathogenesis of AD.